PDF: ASSERT
(2012)Objective
To evaluate whether subclinical episodes of atrial tachyarrhythmia (SCAT) detected by implanted devices are associated with an increased risk of ischemic stroke.
Study Summary
• Subclinical atrial tachyarrhythmias (SCAT) were detected in 10.1% of patients within 3 months after pacemaker or ICD implantation and was associated with a significantly increased risk of stroke or systemic embolism (HR 2.49).• SCAT increased the risk of progression to clinical atrial fibrillation (HR 5.56).
Intervention
Device monitoring for SCAF episodes >190 bpm lasting >6 minutes in patients ≥65 years with hypertension and no history of atrial fibrillation; randomized sub-study of continuous atrial overdrive pacing vs. no pacing.
Study Design
Arms: Array
Outcome
• Ischemic stroke or systemic embolism occurred in 4.2% of patients with SCAF vs. 1.7% without (HR 2.49; p=0.007).• Risk of developing clinical AF was 5.56-fold higher with SCAF.• Annual stroke risk in patients with SCAF and CHADS2 >2 was 3.78%.• No stroke reduction benefit was observed with overdrive pacing.
Bottom Line
Subclinical atrial tachyarrhythmias were common and independently associated with increased risk of ischemic stroke or systemic embolism.
Major Points
- Landmark study that first established the link between device-detected subclinical atrial fibrillation and stroke risk — fundamentally changed how AF is understood as a stroke risk factor.
- Subclinical atrial tachyarrhythmias (rate >190 bpm for >6 minutes) occurred in 10.1% of patients within 3 months and 34.7% by 2.5 years — far more common than previously appreciated.
- Subclinical AF independently associated with 2.5× greater risk of ischemic stroke or systemic embolism (HR 2.49, 95% CI 1.28–4.85, P=0.007) after adjusting for clinical risk factors.
- Only 15.7% of patients with subclinical AF developed clinical AF during follow-up — most device-detected AF remains subclinical, creating a diagnostic and therapeutic gap.
- Risk of stroke increased with longer episode durations — episodes >24 hours carried the highest risk, establishing the concept of 'AF burden' as clinically meaningful.
- Continuous atrial overdrive pacing did not prevent AF (randomized component of the trial) — pacing strategy had no effect on arrhythmia incidence.
- 2,580 patients aged ≥65 with pacemakers/ICDs and hypertension but NO prior clinical AF — a unique population with continuous monitoring capability providing the first prospective evidence.
- CHADS2 score modified the risk: patients with CHADS2 >2 and subclinical AF had stroke rate of 3.78%/year — approaching the threshold where anticoagulation is clearly warranted.
- Set the stage for ARTESIA (2023) and NOAH-AFNET 6 (2023) which tested whether anticoagulation for device-detected subclinical AF reduces stroke — completing the clinical evidence chain.
- Defined the 6-minute threshold for clinically meaningful subclinical AF — though subsequent studies (ARTESIA) used different thresholds, this remained foundational.
Study Design
- Study Type
- Prospective cohort and randomized controlled trial (PROBE)
- Randomization
- Yes
- Blinding
- Blinded endpoint adjudication
- Sample Size
- 2580
- Follow-up
- Mean 2.5 years
- Centers
- 23
Primary Outcome
Definition: Ischemic stroke or systemic embolism
| Control | Intervention | HR/OR | P-value |
|---|---|---|---|
| 0.69%/year | 1.69%/year | 2.49 (1.28–4.85) | 0.007 |
Limitations & Criticisms
- Did not evaluate episodes <6 minutes — the arbitrary 6-minute threshold may miss clinically relevant shorter episodes that still carry embolic risk.
- Unable to assess whether anticoagulation for subclinical AF would reduce stroke — the key therapeutic question remained unanswered until ARTESIA (2023) and NOAH-AFNET 6 (2023).
- Not powered to assess benefit of overdrive pacing — the randomized component was essentially a null result due to insufficient sample size for the pacing question.
- Observational findings for the AF-stroke association despite the trial having a randomized component — the main conclusion is based on the cohort analysis, not the RCT.
- Pacemaker/ICD population has underlying cardiac disease (conduction abnormalities, heart failure) that independently increases stroke risk — results may not generalize to the general population.
- The 6-minute threshold for 'subclinical AF' was arbitrary — subsequent studies used different definitions (ARTESIA used ≥6 minutes, NOAH used ≥6 minutes with ≥1 episode), creating inconsistency.
- Low event rate (~50 strokes total) limited power for subgroup analyses — individual subgroup results should be interpreted with caution.
- Device algorithms for detecting atrial tachyarrhythmias may include non-AF rhythms (atrial tachycardia, far-field oversensing) — not all 'subclinical AF' may be true fibrillation.
- Industry-sponsored by St. Jude Medical (device manufacturer) — potential conflict of interest in promoting device-based monitoring.
Citation
N Engl J Med 2012;366:120–129.